Results 1 to 10 of about 6,578,993 (340)
Current Problems in Cancer, 2009 Multiple myeloma is a typical bone marrow neoplasia of the elderly. On radiographs it is often difficult to detect the typical osteolyses in early stages or in regions where overlying structures hamper image analysis. Osteoporosis may be a sign of tumor infiltration, but it is difficult to distinguish from senile osteoporosis.
Andrea, Baur-Melnyk +1 more
exaly +8 more sources
New England Journal of Medicine, 2004 AbstractMultiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present.
Robert A, Kyle, S Vincent, Rajkumar
+13 more sources
Annual Review of Medicine, 2011 Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
Jacob, Laubach +2 more
+10 more sources
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
Cells, 2022 Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone +5 more
doaj +1 more source
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, 2021 BACKGROUND Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and ...
N. Munshi +27 more
semanticscholar +1 more source
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, 2023 BACKGROUND Survival is poor among patients with triple-class-exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep ...
P. Rodríguez-Otero +21 more
semanticscholar +1 more source
Teclistamab in Relapsed or Refractory Multiple Myeloma.
New England Journal of Medicine, 2022 BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.
P. Moreau +33 more
semanticscholar +1 more source
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
New England Journal of Medicine, 2022 BACKGROUND G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing ...
A. Chari +19 more
semanticscholar +1 more source
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
American journal of hematology/oncology, 2022 Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar +1 more source